Oncology Institute, Inc. (The) (TOI)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$5.91-4.21%
Close 2026-08-31 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
QuarterlyIQ Insights · TOI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.3% |
| Our one-year growth estimate | diamond | 29.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 93.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers · Company calendar date is not available
TOI — credit agreement
Dated 2026-08-21
Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, such other persons joined thereto as a borrower from time to time, and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. The Revolving Loan Agreement provides access to a revolving line of credit facility in the…
Why it matters: The portal was set to launch in mid-August. More use by network doctors would support the stated goal of better care and pathway use.
Supportive ifThe company confirms Starling Nexus launched. It also reports more provider use or better use of clinical pathways.
Worry ifThe company reports a delayed launch, low provider use, or no gain in pathway adherence.
Why it matters: The new line adds access to credit, but the supplied filing summary gives no size or key terms. Watch for use and its effect on debt and liquidity.
Watch forA filing or results report says the line is available but unused. Cash stays at or above the June 30 level of $41.1 million.
Also watch forA filing or results report shows the line drawn and cash below $41.1 million, or new limits on access to the line.
Why it matters: Q3 is the first test of the new $2 million to $7 million 2026 profit range. Florida lives are still ramping.
Supportive ifQ3 adjusted EBITDA is at least $500,000, within the company's stated $500,000 to $1.5 million range.
Worry ifQ3 adjusted EBITDA is below zero, missing the low end of the stated range.
Why it matters: The July refinancing used about $11 million of cash to repay debt. A fall below the March cash level would add to liquidity concerns.
Worry ifReported cash is below $30.1 million, the March 31 balance. The company also reports more borrowing or cash pressure.
Less concerning ifReported cash is at least $41.1 million, the June 30 balance, with no new liquidity strain.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$277 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $718 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,979 loss on $10,000 · 49.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company raised its 2026 revenue range after strong first-half results. Revenue below the old range would weaken that growth signal.
Supportive ifReported 2026 revenue is at least $650 million, meeting the low end of updated guidance.
Worry ifReported 2026 revenue is below $630 million, missing the low end of the prior range.